Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | CheckMate 227: chemo-free NSCLC treatment

Solange Peters • 30 Sep 2019
ESMO 2019
Lung Cancer Non-Small Cell Lung Cancer Ipilimumab Nivolumab
CheckMate 227

Solange Peters, MD, PhD, University Hospital Vaudois, Lausanne, Switzerland, discusses the final analysis of the part 1 CheckMate-227 trial (NCT02477826), which investigated the use of nivolumab, or nivolumab plus ipilimumab, or nivolumab plus platinum-doublet chemotherapy, compared to platinum doublet chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Solange Peters

2:01
Unanswered questions on immunotherapy for lung cancer
Solange Peters • 11 Sep 2022
3:09
ESMO 2022: Highlights from the Presidential Symposium
Solange Peters • 11 Sep 2022
3:18
Subgroup analysis of PEARLS/KEYNOTE-091: PD-L1 expression and outcomes of pembrolizumab
Solange Peters • 11 Sep 2022
2:42
Aligning the educational resources put out by ESMO
Solange Peters • 30 Sep 2019

Related Videos

3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals